
Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸
@tomvarghesejr
Professor @uofusurgery ; Chief, Gen Thoracic Surgery @UofUHealth ; CVO @huntsmancancer; Past Prez @UnivSurg ; Editor-in-chief @acsJACS ; RTs ≠ endorsement.
ID: 1323379315
http://healthcare.utah.edu/fad/mddetail.php?physicianID=u6001828 02-04-2013 22:12:08
368,368K Tweet
25,25K Takipçi
9,9K Takip Edilen












Linda Martin CTSurgSocMedNetwork General Thoracic Surgical Club Completely agree No role for CROSS in esophageal/GEJ adenoCA expect for patients not expected to tolerate FLOT Daniela Stephanie G Worrell, MD FACS Biniam Kidane Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Sheraz Markar Lorenzo Ferri MD PhD

Elliot Servais, MD, FACS Linda Martin CTSurgSocMedNetwork General Thoracic Surgical Club Daniela Stephanie G Worrell, MD FACS Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Sheraz Markar Lorenzo Ferri MD PhD A lot to digest…and caveats in both ESOPEC and MATTERHORN about the surgeries and the control arms … That being said, I totally agree that this reinforces that in those patients with adeno who can tolerate FLOT, that should be the preferred backbone therapy



Gerry Fried talks technology, crucial conversations and innovation youtu.be/UIHj8tl-PsA?si… via YouTube #innovation #leadership #surgery #ArtificialIntelligence McGill University Liane Feldman MD Lawrence Lee MD PhD SAGES is in Tampa in 2026! Journal of the American College of Surgeons (JACS) mark talamini Steven Schwaitzberg, MD Patricia Sylla JOGS

Scott Silvestry MD ASGBI RCSI The Royal College of Surgeons of England RACSurgeons Annals of Surgery Journal of the American College of Surgeons (JACS) AMERICAN SURGICAL CO ASCRS_1 Neil Smart Neil Mortensen Neil Floch MD Lahey Surgery McGill Surgery Philip Schauer, MD Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Matthew Albert mary hawn Sherry Wren Fergal Fleming Arman Erkan Eric Pauli

Elliot Servais, MD, FACS Linda Martin CTSurgSocMedNetwork General Thoracic Surgical Club Daniela Biniam Kidane Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Sheraz Markar Lorenzo Ferri MD PhD Just a note, there were no esophageal cancer patients in this trial (30% GEJ), OS analysis pending and we need better bio markers…probably one approach for all is not the answer! FLOT is rough and I’m not completely abandoning Checkmate 577…but D-FLOT is exciting!!

